GlassScriptPhysician profile
Ross M Langley
NPI 1851381115
$731.77
in general payments reported to CMS, 2019-2025
16 companies · $17.50 in 2025
The $17.50 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $200 · 2021: $139 · 2022: $23.31 · 2023: $116 · 2024: $57.67 · 2025: $17.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.37 | 2020-2023 | |
| Therapeuticsmd, INC. | $108.30 | 2019-2021 | |
| Allergan, INC. | $76.27 | 2019 | |
| Coopersurgical, INC. | $64.46 | 2021-2024 | Paragard T 380a |
| Pfizer INC. | $48.04 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.20 | 2019-2020 | |
| Astellas Pharma US INC | $25.62 | 2023 | Veozah |
| Mayne Pharma Commercial LLC | $23.31 | 2022 | |
| Biogen, INC. | $21.24 | 2024 | Zurzuvae |
| Exeltis, USA INC. | $20.62 | 2020 | |
| Organon LLC | $17.75 | 2023 | Nexplanon |
| Millicent US INC | $17.50 | 2025 | Intrarosa, Femring |
| Duchesnay USA Incorporated | $16.61 | 2019 | |
| Lupin INC. | $15.89 | 2019 | |
| Merck Sharp & Dohme LLC | $12.37 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $8.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Langley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.